#United States #Boston #financial results #Haemonetics #Fiscal Year 2027

Haemonetics Corporation's Q1 Fiscal 2027 Financial Results

Haemonetics Corporation, a reputable global medical technology firm, has announced its financial results for the first quarter of the fiscal year 2027, which concluded on June 27, 2026. This announcement was made public on August 6, 2026, and the details can be found on the company's Investor Relations website at www.haemonetics.com.

Overview of the Q1 Results

During this quarter, Haemonetics' performance reflected its ongoing commitment to enhancing healthcare quality and efficiency through innovative medical technologies. The earnings report provides insight into various aspects of the company's operations, including revenue generation, profit margins, and overall growth in key segments.

Conference Call and Webcast

In conjunction with the release of these results, Haemonetics will host a conference call and a live webcast aimed at investors and analysts. This interactive session is scheduled for August 6, 2026, at 8:00 AM ET. Interested parties can register for the session and obtain dial-in details, along with a personalized PIN, through the company's website. It’s advisable for participants to join the call about 10 minutes early to ensure a smooth start.

Follow-Up and Additional Information

For stakeholders unable to attend the live event, a replay of the conference call will be accessible starting from 11:00 AM ET on the same day. This replay will remain available for one year, allowing investors to catch up on discussions around the fiscal results.

Haemonetics' Commitment to Healthcare

Haemonetics has positioned itself at the forefront of medical technology innovation. The company’s Apheresis business is recognized for its proprietary technologies aimed at improving the safety, yield, donor satisfaction, and operational efficiency within the plasma and blood collection industry. Furthermore, Haemonetics' MedSurg business sector provides advanced Blood Management Technologies which assist healthcare professionals in making informed treatment decisions while optimizing management of blood products.

Additionally, their Interventional Technologies, which include advanced vascular closure systems and sensor-guided solutions, are designed to enhance procedural effectiveness and improve the patient care experience overall.

To learn more about Haemonetics and its robust portfolio, please visit their official website at www.haemonetics.com.

Investor Relations Contacts

For any investment-related inquiries, stakeholders can reach out to:

• - Olga Guyette, Vice President of Investor Relations, at (781) 356-9763 or via email at [email protected]
• - David Trenk, Senior Manager of Investor Relations, at (203) 733-4987.

For media inquiries, please contact:

• - Josh Gitelson, Senior Director of Global Communications, at (781) 356-9776.

By maintaining transparency and providing access to essential financial data, Haemonetics continues to foster trust with its investors and stakeholders.